Sanofi has not had the success it was hoping for with its oral BTK inhibitors, acquired as part of its $3.7 billion buyout of Principia Biopharma, but can now point to a win for rilzabrutinib in ...

A bigger store. Twice the number of gas pumps and parking spots. Bulldozing for new space. Here's what's in the works, according to officials' discussions at a recent city planning commission.